

Press Release



Announcement regarding GnRH antagonist, RELUMINA® Tablets 40mg

TOKYO, February 14th, 2020 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") has announced that it has inherited the approval for 「GnRH antagonist, RELUMINA® Tablets 40mg」 as of today, which has been licensed-in from Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka, hereinafter "Takeda").

The changes are as below.

	Current notation	New notation
Marketing Authorization Holder	Takeda Pharmaceutical Company Limited	ASKA Pharmaceutical Co., Ltd.

There is no fee associated with this inheritance and change.

ASKA is a specialty pharma within the therapeutic area of Obstetrics and gynecology and through the above product, wishes to further contribute to women's health and their livelihood.